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Resveratrol is a natural compound that mimics the antioxidant and antiaging effects of caloric restriction, mainly 2 
mediated through SIRT1, a deacetylase that induces longevity and neuroprotection. We aimed to analyze the effects of 3 
resveratrol on the brain status of control non-transgenic (NoTg) and AD transgenic (3xTg-AD) mice to discern the 4 
mechanisms involved in a potential inducement of resilience against age-related neurodegeneration and Alzheimer’s 5 
disease (AD). Mice were fed with a diet supplemented with 100 mg/kg of trans-resveratrol from 2 months of age during 6 
10 months. Resveratrol administration induced complete protection against memory loss and brain pathology in 3xTg-7 
AD mice, and also induced cognitive enhancement in healthy NoTg mice. Resveratrol improved exploration and 8 
reduced anxiety in both mouse strains, indicative of well-being. Resveratrol reduced the presence of Aβ and p-tau 9 
pathology in the hippocampus of the 3xTg-AD mouse. Proteostasis analysis showed the following in both NoTg and 10 
3xTg-AD mice: (i) increased levels of the amyloid degrading enzyme neprilysin; (ii) reduction of the amyloidogenic 11 
secretase BACE1, and (iii) increase of proteasome protein levels and enhancement of proteasome activity. Resveratrol 12 
also increased AMPK protein levels, then upregulating the SIRT1 pathway, as shown by the activation of PGC-1α and 13 
CREB in both mice, resulting in further beneficial changes. Our data demonstrated that resveratrol induces cognitive 14 
enhancement and neuroprotection against amyloid and tau pathologies. Improvement of proteostasis by resveratrol, in 15 
both healthy and AD mice, suggests that it is a mechanism of brain resilience and defense against neurodegeneration 16 
caused by the accumulation of aberrant proteins. 17 
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The progressive increase in life expectancy has led to an increase in the incidence of age-related diseases, including 34 
dementia [1]. Alzheimer’s disease (AD) is the most common cause of dementia in the elderly [2,3], characterized by 35 
brain depositions of amyloid-β (Aβ) and hyperphosphorylated tau (p-tau), leading to synapse dysfunction, cognitive and 36 
memory deficits and, finally death [4,5]. To date, there is no effective treatment of AD, except for temporarily 37 
symptom-relieving drugs [6,7]. Finding a treatment is crucial to reducing the overall effects of aging, increasing 38 
healthspan in humans. 39 
Resveratrol is a polyphenol found in common dietary sources such as grapes, berries, peanuts and red wine, and in some 40 
herbal remedies [8,9]. In animal models, resveratrol exhibits a wide spectrum of potential therapeutic activities, 41 
including antioxidant, anti-inflammatory, neuroprotective and longevity-promoting properties [9-11]. Experimental 42 
studies suggest that resveratrol is active against AD pathogenesis [12-15]. First clinical trials of dietary supplementation 43 
with resveratrol in AD have been completed, with encouraging changes such as attenuation of the decline of 44 
cerebrospinal fluid (CSF) levels of Aβ species [16,17], and reduction of plasma levels of pro-inflammatory markers and 45 
attenuation of cognitive and functional decline [17]. Furthermore, improvement of cognitive performance reported in 46 
trials with non-demented older adults [18,19] suggests a preventive potential of resveratrol. Studies with transgenic 47 
mouse models of AD showed that resveratrol intake protected against Aβ plaque formation in Tg19959 [20] and 48 
APP/PS1 mice [21,22]. Increased synaptic markers and preservation of recognition memory were also found in 49 
resveratrol treated APP/PS1 mice [22]. Moreover, in the p25 mouse model of AD and tauopathies, 50 
intracerebroventricular delivery of resveratrol prevented impairment of fear conditioning associative learning and 51 
reduced the levels of markers of apoptosis and astrogliosis [23].  52 
The hypothesis of the most widely accepted mechanism comprises that resveratrol mimics the antioxidant and antiaging 53 
effects of caloric restriction [24,25], which are mediated by SIRT1 [22,26]. SIRT1 is a nicotinamide-adenine 54 
dinucleotide (NAD
+
)-dependent deacetylase associated with anti-aging pathways [27] that induces protective effects 55 
against AD brain pathology through regulating the acetylation homeostasis of key proteins [28-30]. There is 56 
controversy over whether resveratrol may be a direct activator of SIRT1 [31] or whether SIRT1 is indirectly activated 57 
by other resveratrol-induced pathways [32,33]. Recent evidences suggest that resveratrol increases adenosine 58 
monophosphate-activated protein kinase (AMPK) activity, leading to an increase of NAD
+
 levels, which in turn 59 
enhances SIRT1 activity [34,35].  60 
At the cellular level, resveratrol demonstrated protective effects against oxidative stress and inflammatory processes 61 
induced by Aβ in PC12 cell line [36] and human stem cells [37]. Resveratrol promotes Aβ clearance through 62 
enhancement of proteasome-dependent proteolysis, as shown in cell lines expressing APP695, either wild-type or 63 
harboring the Swedish mutation [38] and in a C.elegans model of AD [39]. Resveratrol was also shown reducing Aβ 64 
levels of transgenic cell line and worm models by autophagy and lysosomal degradation activated by AMPK signaling 65 
[21,39]. Furthermore, resveratrol may decrease Aβ generation by favoring the non-amyloidogenic pathway of APP 66 
degradation [26]. 67 
One of the molecular changes of aging that might contribute to the development of AD is the deficiency in cellular 68 
control mechanisms that degrade aberrant proteins [40]. Clearance of Aβ and tau through proteolytic mechanisms 69 
include ubiquitin-proteasome system (UPS), autophagy-lysosomal system, and extracellular proteases [41]. 70 
Furthermore, protein folding stress in the endoplasmic reticulum may activate the unfolded protein response aimed to 71 
restore proteostasis, preferentially through autophagy in the AD brain [42], or trigger apoptosis of irreversible damaged 72 
cells [43]. However, the stress responsivity of the different AD mouse models is highly variable [44]. UPS is the 73 
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primary selective mechanism to maintain proteostasis in eukaryotic cells and is involved in many nerve cell functions, 74 
such as plasticity and memory [45,46]. Increasing evidence postulates functional alterations of UPS and its molecular 75 
components as causes of early changes in AD pathology [47]. Heat shock protein 70 (Hsp70) facilitates the 76 
ubiquitination of aberrant proteins through interaction with the carboxyl-terminus of Hsp70 interacting protein (CHIP) 77 
and the E3 ligase [48]. Polyubiquitinated proteins are recognized by the proteasome complex for subsequent proteolytic 78 
degradation by the 20S catalytic core [49,50]. 79 
Studies with AD mouse models were needed to confirm resveratrol-induced cognitive improvement and further unveil 80 
its mechanism of action against AD-like neurodegeneration. We aimed to analyze the effects of the administration of 81 
resveratrol in mice as a preventive and therapeutic agent, with emphasis in APP processing and UPS activity, and their 82 
effects on learning and memory. For this purpose, we treated both control non-transgenic mice (NoTg) and triple-83 
transgenic mice for AD (3xTg-AD) with a daily dose of 100 mg/kg of resveratrol during 10 months. Our results 84 
demonstrated that resveratrol administration induced complete protection against memory loss and brain pathology in 85 
AD mice. Furthermore, we showed that resveratrol induced proteostasis enhancement in both 3xTg-AD and healthy 86 
NoTg mice. We propose that proteostasis enhancement increases brain resilience against neurodegeneration. New 87 
insights into the mechanisms of resveratrol in preclinical studies may aid in the design of preventive strategies against 88 
AD. 89 
  90 
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Materials and methods 91 
Animals 92 
Male 3xTg-AD mouse strain harboring familial AD mutations of the APP (APPSwe) and the Presenilin 1 (PS1M146V), and 93 
a tau gene mutation (TauP301L) [51] was used in the present study. These mice mimic many of the critical hallmarks of 94 
AD as Aβ and tau pathologies, impaired learning and memory, presence of behavioral and psychological symptoms of 95 
dementia (BPSD)-like, and oxidative stress [30,52]. Furthermore, 3xTg-AD mice reproduce the temporal course and 96 
areas affected by amyloid and tau pathology of AD neuropathology [53]. Control NoTg mice had the same genetic 97 
background hybrid 129 × C57BL/6 than 3xTg-AD mice [51]. Genotypes were confirmed by PCR analysis of DNA 98 
obtained from tail biopsies. Animals were individually housed in Makrolon® cages under standard laboratory 99 
conditions of food and water ad libitum, 22 ± 2°C, and 12h:12h light-dark cycle. Animal breeding, treatment, and 100 
behavioral studies were performed at the University of Barcelona Animal House (UB, Barcelona, Spain). Animal 101 
handling and experimental procedures were approved by the Ethics Committee for animal experimentation (CEEA) of 102 
the University of Barcelona (UB) (Ref: DAAM 6523, CEEA), in accordance with the Decree 214/1997 of the 103 
Generalitat of Catalonia and the Directive 2010/63/EU of the European Union for animal experiments.  104 
 105 
Resveratrol administration 106 
At 2 months of age, mouse standard diet (2018 Teklad Global 18 % Protein Rodent Maintenance Diet, Harlan) was 107 
supplemented with 1 g/kg of trans-resveratrol (Mega Resveratrol, Candlewood Stars, Inc., CT, USA). Resveratrol 108 
groups (RV) received 100 mg/kg bw/day during 10 months. The period of 2 to 12 months of age covers a broad period 109 
of the AD pathology progression in 3xTg-AD mice, from the pre-symptomatic to the advanced pathology phase. 110 
Control groups (Ct) received standard diet. The experimental groups were as follows: NoTg-Ct (n = 14), NoTg-RV (n = 111 
12), 3xTg-Ct (n = 10) y 3xTg-RV (n = 10). No significant differences were found among the treatment groups in diet 112 
intake or in body weight along the study (not shown). 113 
 114 
Behavioral and cognitive tests 115 
Animals were tested for behavior and cognitive improvement at 10 months of the chronic resveratrol treatment, at 12 116 
months of age. The behavioral tests were carried out at the Unitat d'Experimentació Animal of the Faculty of 117 
Psychology of the University of Barcelona (Campus Mundet, UB). Selected BPSD-like symptoms and cognitive tests 118 
were analyzed as previously described [54,55]. Briefly, the Open field test was used to evaluate vertical and horizontal 119 
locomotor activity and general behavior in a white chamber during 5 min. The Boissier’s 4 hole-board test was utilized 120 
to evaluate exploratory behavior by measuring head-dipping during 5 min. The Dark & Light test was employed to 121 
assess anxiety during 5 min in a black compartment connected to a lit compartment. The Novel object recognition 122 
(NOR) test was used to evaluate recognition memory, and is based on the spontaneous tendency of rodents to spend 123 
more time exploring a novel object than a familiar one. The animals were submitted to a 10 min acquisition trial in the 124 
presence of two identical novel objects (A1 + A2). A 10 min retention trial occurred 2 h later, replacing object A1 with 125 
object B; and another 10 min retention trial took place 24 h later, replacing object A2 with object C. Discrimination 126 
index was calculated as [novel (t) – familiar (t)] / [total time (t) at novel + familiar]. The Morris water maze (MWM) 127 
test was employed to assess spatial learning and memory, and consisted of 1 day of cue learning, 6 days of learning 128 
acquisition, and 1 final day of memory retrieval. Animals were trained to locate the hidden platform in a circular water 129 
tank by relying on distinctive landmarks as visual cues (four trial sessions of 60 sec per day). On the last day, the 130 
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platform was removed and the mice performed a 60 sec probe trial to test learning retention. A computerized tracking 131 
system (SMART, Panlab S.A., Barcelona, Spain) was employed to measure escape latency, and distances and quadrants 132 
covered. At the end of the behavioral tests, the animals were decapitated under light anesthesia and the hippocampus 133 
and cerebral cortex were dissected and stored at −80°C for further analysis. 134 
 135 
Western blotting 136 
Protein extracts from hippocampus and cerebral cortex were obtained in 50 mM Tris/HCl (pH 7.6), 150 mM NaCl, 1% 137 
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol and 10 µg/mL aprotinin. Aliquots of 30 µg of 138 
protein were analyzed for Western blot analysis by standard procedures [30,56]. The following antibodies were 139 
employed for immunodetection: Aβ clone 6e10, sAPPα, sAPPβ, C-terminal fragment of APP (APP-CTF), a disintegrin 140 
and metalloproteinase 10 (ADAM10), AMPK, phosphorylated AMPK (p-AMPK), beta-site APP cleaving enzyme 1 141 
(BACE1), cAMP response element-binding protein (CREB), phosphorylated CREB (p-CREB), Hsp70, IDE, neprilysin, 142 
acetylated p53 (ac-p53), peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), proteasome 20S core 143 
subunits, postsynaptic density protein 95 (PSD95), SIRT1, synaptophysin, acetylated tau (ac-tau), p-tau clone AT8, 144 
total tau clone HT7, and ubiquitin. Details of primary antibodies used are presented in Supplementary Table 1. 145 
Secondary antibodies were peroxidase-conjugated (1:2000) (GE Healthcare). Quantitative values of the correspondent 146 
bands were detected by a chemiluminiscence method using VersaDoc Imaging System 5000 (Bio-Rad, USA). Optical 147 
density of the studied proteins was normalized to actin or tubulin. Protein levels were calculated and expressed relative 148 
to the amount in the NoTg-Ct mouse group. 149 
 150 
Proteasome activity assay 151 
Proteasomal activity was evaluated in the brain cortex by the Proteasome-Glo™ Assay Systems (Promega, USA). 152 
Cortex tissues in ice-cold PBSE (PBS, 5 mM EDTA, pH 7.4) at a ratio of 1:10 (buffer/tissue; v/w) were sonicated on 153 
ice for 20 sec with a 1 sec pulse length, twice, using a pulsed homogenizer. Obtained tissue lysates were centrifuged at 154 
13,000 g for 10 min at 4°C, and the supernatants were subjected to protein quantification employing the Bradford assay. 155 
The supernatants were diluted with cold PBSE at a concentration of 0.2 mg/ml total protein. A total of 10 µg of protein 156 
(50 µl of 0.2 mg/ml diluted extract) was added to 50 µl of the luminescent reagent containing the Ultra-Glo™ 157 
Luciferase and the specific luminogenic substrate (Suc-LLVY-Glo™ for the chymotrypsin-like activity assay, Z-LRR-158 
Glo™ for the trypsin-like activity assay, or Z-nLPnLD-Glo™ for the caspase-like activity assay) in a 96-well plate. 159 
Solutions were mixed for 30 sec at 400 rpm and incubated for 30 min at room temperature. The resulting luminescence 160 
was measured twice with an integration time of 1 sec utilizing the Orion II Microplate Luminometer (Titertek-Berthold, 161 
Germany). In this setup, luminescence signal intensity corresponded to proteasomal proteolytic activity. The 162 
proteasomal inhibitor was used (MG-132, 10 μM) to calculate unspecific background activity. 163 
 164 
Statistical analysis 165 
Results are expressed as mean ± SEM. Data were analyzed with analysis of variance (ANOVA) procedures; factors 166 
were genotype and treatment. Two-way repeated measures ANOVA was employed to analyze the acquisition task of 167 
the MWM test. All other data were analyzed by regular two-way ANOVA followed by main effect analysis for 168 
comparison of groups where interaction between factors was present. Statistical analyses were performed using 169 




Resveratrol administration induced beneficial effects on BPSD-like behavior 172 
Ten-month resveratrol treatment induced a significant protective effect against the AD-like pathology underlying 173 
BPSD-like behavioral alterations in 12 month-old mice (Fig. 1a-e). In the Open field test, 3xTg-Ct mice demonstrated 174 
lower vertical explorations (rearings) compared to NoTg mice (Fig. 1a). Resveratrol administration increased the 175 
number of total rearings in both NoTg-RV and 3xTg-RV mice [genotype, F(1, 39) = 48.29, p < 0.0001; and treatment, 176 
F(1, 39) = 4.219, p = 0.0467]. Moreover, 3xTg-Ct mice showed lower horizontal mobility compared to NoTg mice (Fig. 177 
1b). Resveratrol treatment also increased the total distance covered in both strains [genotype, F(1,42) = 40.75, p < 178 
0.0001; and treatment, F(1,42) = 7.343, p = 0.0097]. In the Boissier’s 4 hole-board test, 3xTg-Ct mice showed higher 179 
latency for first-hole exploration compared to NoTg mice (Fig. 1c). Resveratrol treatment reduced latency in both 180 
NoTg-RV and 3xTg-RV mice [genotype, F(1,42) = 28.88, p < 0.0001; and treatment, F(1,42) = 6.349, p = 0.0156]. In 181 
the Dark & Light box test, 3xTg-Ct mice presented a higher anxiety response compared to NoTg mice (Fig. 1d-e). 182 
Resveratrol administration increased, in both mouse, strains the number of entries into the lit area (Fig. 1d) [genotype, 183 
F(1,42) = 11.89, p = 0.0013; and treatment, F(1,42) = 5.027, p = 0.0303] and the time spent in the lit area (Fig. 1e) 184 
[genotype, F(1,42) = 9.360, p = 0.0039; and treatment, F(1,42) = 4.844, p = 0.0333]. 185 
 186 
Resveratrol administration induced beneficial effects on cognitive behavior 187 
Ten-month resveratrol treatment induced a significant protective effect against the AD-like pathology involved in 188 
learning and memory capacities (Fig. 2a-f). Cognition was preserved in 12-month-old 3xTg-RV mice, in addition to 189 
inducing cognitive enhancement effects in NoTg-RV mice. In the NOR test, 3xTg-Ct mice exhibited a deficit of 190 
recognition memory, while NoTg-RV and 3xTg-RV mice increased their capacity to remember familiar objects at 2 h 191 
(Fig. 2b) [genotype, F(1,36) = 4.195, p = 0.0479; and treatment, F(1,36) = 8.826, p = 0.0053] and at 24 h (Fig. 2c) 192 
[treatment, F(1,36) = 6.759, p = 0.0134; and interaction genotype × treatment, F(1,36) = 4.256, p = 0.0464]. In the 193 
MWM test, the distances covered to locate the platform decreased along the 6 days of place-task acquisition (Fig. 2d) in 194 
3xTg-RV mice, similar to NoTg mice; however, two-way repeated measures ANOVA did not show significant 195 
differences between groups. Nevertheless, in learning retrieval, 3xTg-Ct mice swam at random in the pool unaware of 196 
the former position of the escape platform, while both NoTg groups and that of the 3xTg-RV mice remembered the 197 
quadrant where the platform was situated (Fig. 2e) [genotype, F(1,42) = 5.537, p = 0.0234; and interaction genotype × 198 
treatment, F(1,42) = 6.645, p = 0.0135], indicating better memory response after resveratrol treatment. In addition, 199 
resveratrol administration increased swimming speed in both strains (fig. 2f) [treatment, F(1,42) = 4.081, p = 0.0498]. 200 
 201 
Resveratrol administration induced neuroprotective effects against amyloid-β pathology 202 
Analysis of immunoblotting from hippocampus tissue showed higher protein levels of total APP (Fig. 3a) in 3xTg-AD 203 
mice as compared with NoTg mice [genotype, F(1,20) = 48.59, p < 0.0001], as expected. Furthermore, the levels of Aβ 204 
peptides, such as APP-CTF (Fig. 3b) [genotype, F(1,20) = 41.45, p < 0.0001; treatment, F(1,20) = 8.680, p = 0.0080; 205 
and interaction genotype × treatment, F(1,20) = 6.687, p = 0.0177], Aβ 6e10 (Fig. 3c) [genotype, F(1,15) = 10.45, p = 206 
0.0056; treatment, F(1,15) = 6.976, p = 0.0185; and interaction genotype × treatment, F(1,15) = 4.709, p = 0.0465], and 207 
sAPPβ (Fig. 3d) [genotype, F(1,23) = 4.528, p = 0.0443; and interaction genotype × treatment, F(1,23) = 9.954, p = 208 
0.0044], were increased to a higher degree in 3xTg-Ct compared to NoTg mice, as characterized for AD pathogenesis. 209 
Resveratrol treatment induced a decrease in amyloid pathology, by a recovery of the APP-CTF (Fig. 3b), Aβ 6e10 (Fig. 210 
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3c), and sAPPβ (Fig. 3d) protein levels in 3xTg-RV mice, due to a decrease of BACE1 secretase levels (Fig. 3e) 211 
[treatment, F(1,19) = 4.993, p = 0.0377] and the increase of the neprilysin protease (Fig. 3f) [treatment, F(1,20) = 5.334, 212 
p = 0.0317] in both strains. These results confirm the effect of resveratrol on Aβ pathology mitigation. The attenuation 213 
of the amyloidogenic pathway and the increased proteostasis exerted an effect on both strains treated with resveratrol; 214 
however, no significant changes were observed in the levels of the neuroprotector sAPPα peptide (Supplementary Fig. 215 
1a). Resveratrol increased secretase ADAM10 levels with borderline statistical significance (Supplementary Fig. 1b) 216 
[treatment, F(1,16) = 4.218, p= 0.0567]. Protease IDE was reduced in 3xTg-AD mice, but resveratrol did not change 217 
levels (Supplementary Fig. 1c) [genotype, F(1,14) = 4.789, p = 0.0461]. 218 
 219 
Resveratrol administration induced neuroprotective effects against tau pathology 220 
Analysis of immunoblotting from hippocampal tissue revealed elevated protein levels of total tau (Fig. 3g) in 3xTg-AD 221 
mice as compared with NoTg mice [genotype, F(1,20) = 24.36, p < 0.0001], as expected. The protein levels of p-tau 222 
(Fig. 3h) [genotype, F(1,24) = 10.72, p = 0.0032; treatment, F(1,24) = 10.11, p = 0.0040; and interaction genotype × 223 
treatment, F(1,24) = 5.313, p = 0.0301], and of ac-tau (Fig. 3i) [genotype, F(1,25) = 12.53, p = 0.0016; treatment, 224 
F(1,25) = 8.924, p = 0.0062; and interaction genotype × treatment, F(1,25) = 5.562, p = 0.0265] were increased to a 225 
greater degree in 3xTg-Ct compared to NoTg mice, as characterized for AD pathogenesis. Resveratrol treatment 226 
protected against tau pathology, in that it normalized p-tau (Fig. 3h) protein levels in 3xTg-RV mice, due to a decrease 227 
of ac-tau (Fig. 3i) protein levels in 3xTg-RV mice. Deacetylation of tau protein allows it to be degraded by the UPS. 228 
These results confirm the effect of resveratrol on tau pathology mitigation. 229 
 230 
Resveratrol administration enhanced ubiquitin-proteasome system activity 231 
Immunoblotting analysis demonstrated higher Hsp70 protein levels (Fig. 4a) [genotype, F(1,20) = 35.84, p < 0.0001; 232 
treatment, F(1,20) = 6.283, p = 0.0209; and interaction genotype × treatment, F(1,20) = 7.517, p = 0.0126] and 233 
ubiquitinated proteins levels (Fig. 4b) [genotype, F(1,18) = 5.867, p = 0.0262; treatment, F(1,18) = 10.53, p = 0.0045; 234 
and interaction genotype × treatment, F(1,18) = 6.450, p = 0.0205] in 3xTg-Ct compared to the hippocampus of NoTg 235 
mice. Resveratrol treatment restored Hsp70 (Fig. 4a) and ubiquitinated (Fig. 4b) protein levels in 3xTg-RV mice. 236 
Moreover, resveratrol treatment induced an enhancement of proteasome 20S core subunits levels (Fig. 4c) [treatment, 237 
F(1,28) = 12.34, p = 0.0015] in the hippocampus of NoTg-RV and 3xTg-RV mice. A tendency to a decrease in 238 
proteasome protein levels in 3xTg-Ct mice did not reach significance. Besides, resveratrol also induced enhancement of 239 
proteasome 20S core subunits levels (Fig. 4d) [treatment, F(1,20) = 11.02, p = 0.0034] in the cerebral cortex of both 240 
strains. Accordingly, resveratrol treatment induced an increase of trypsin-like activity (Fig. 4e) [treatment, F(1,29) = 241 
7.638, p = 0.0098] in the cerebral cortex of both strains, but no changes were detected in chymotrypsin-like 242 
(Supplementary Fig. 2a) and caspase-like activity (Supplementary Fig. 2b). These results showed the neuroprotective 243 
effects of resveratrol for aberrant proteins disposal by enhancement of the brain proteasome function. 244 
 245 
Resveratrol administration activates SIRT1 pathway regulators 246 
Immunoblotting analysis did not show significant variations of SIRT1 protein levels in the hippocampus of both strains, 247 
or after resveratrol treatment (Fig. 5a). However, SIRT1 activity was confirmed by the diminution of p53 acetylated in 248 
both strains after resveratrol treatment, indicative of SIRT1 deacetylation action (Fig. 5b) [treatment, F(1,20) = 9.208, p 249 
= 0.0065]. Moreover, resveratrol treatment incremented p-AMPK protein levels (Fig. 5c) [treatment, F(1,23) = 8.867, p 250 
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= 0.0067] in both strains, which subsequently produces an increase of the substrate NAD
+
, indicative of SIRT1 pathway 251 
activation. Resveratrol promoted the increase of p-CREB (Fig. 5d) [treatment, F(1,20) = 15.75, p = 0.0008] by SIRT1 252 
pathway in both strains. Moreover, PGC-1α protein levels were lower in 3xTg-AD compared to NoTg mice, indicative 253 
of mitochondria dysfunction (Fig. 5e); however, resveratrol administration increased protein levels in both strains 254 
[genotype, F(1,23) = 8.937, p = 0.0065; treatment, F(1,23) = 7.419, p = 0.0121]. 255 
 256 
Resveratrol administration does not modulate neurotrophism or plasticity. 257 
Immunoblotting demonstrated that PSD95 (Supplementary Fig. 3a) [genotype, F(1,16) = 21.79, p = 0.0003], and 258 
Synaptophysin (Supplementary Fig. 3b) [genotype, F(1,23) = 5.960, p = 0.0227] protein levels were higher in NoTg as 259 
compared with 3xTg-AD hippocampal tissue. However, resveratrol treatment had no effect, and protein levels were 260 
unchanged. 261 




Chronic administration of resveratrol in the 3xTg-AD mouse model of AD, and in normal NoTg mice, confirmed its 264 
potential usefulness for the treatment and prevention of AD, and further extended previous mechanisms in findings 265 
from in vitro [38,57,58] and in vivo studies [20,22,23,26,59,60].  266 
Our results showed that resveratrol administration induced total protection against cognitive loss in 3xTg-AD mice and 267 
memory enhancement in control mice, in hippocampus-based tests of learning and memory. The hippocampus is an 268 
area selectively affected by AD [61], and the deterioration of hippocampal circuits contributes greatly to the devastating 269 
effects of memory loss in the disease [62]. Several regions of cerebral cortex are also deeply affected by AD pathology 270 
[63]. Both hippocampus and cerebral cortex shown accumulation of Aβ and p-tau and neurodegenerative changes in 12 271 
months old 3xTg-AD mice [53]. 272 
The spatial learning and memory analyzed in the MWM test are considered to be associated with optimal functioning of 273 
hippocampal circuits [64,65]. Untreated 3xTg-AD mice exhibited deficient learning and impaired retention in the 274 
MWM task, as reported previously [52]. This task, which is dependent on the dorsal hippocampus [66], revealed totally 275 
protection in 3xTg-AD mice by means of resveratrol administration. Furthermore, 3xTg-AD mice showed impairment 276 
of recognition memory evaluated by the NOR test [67], a task involving the hippocampus and brain cortex regions 277 
[68,69]. Recognition memory was also preserved by resveratrol administration in 3xTg-AD mice. The neuroprotection 278 
of resveratrol against cognitive impairment in 3xTg-AD mice confirmed previous studies in the SAMP8 mouse model 279 
of pathological aging and AD [26,59] and in APP/PS1 AD transgenic mice [22]. Furthermore, recognition memory was 280 
generally improved by resveratrol, demonstrating cognitive enhancement in NoTg mice. Benefits of resveratrol 281 
administration were also proven by reversal of the abnormal behaviors included in the BPSD phenotype, which 282 
comprise very prevalent neuropsychiatric symptoms in patients with AD [70]. In these non-cognitive behaviors, 283 
resveratrol also exhibited beneficial effects in NoTg mice, which is indicative of enhanced well-being, such as increased 284 
exploration and decreased anxiety behaviors. Considering the results of cognitive and non-cognitive behavior, a 285 
preventive and therapeutic effect of resveratrol against AD dementia has been demonstrated. The benefits in neuronal 286 
activity demonstrated in control-strain mice suggest an enhancement in brain resilience that would decrease the risk of 287 
AD. 288 
Analysis of brain pathological changes in 3xTg-AD mice demonstrated that resveratrol induced a decrease in amyloid 289 
and tau pathologies to levels similar to those in the control strain. Only higher levels of APP and total tau were observed 290 
in all 3xTg-AD mouse groups compared to NoTg mice, in agreement to their transgene expression [51]. Western blot 291 
immunodetection results of amyloidogenic fragments (Aβ and CTF) were conclusive of total protection. The fight 292 
against the cerebral excess of Aβ is one of the main objectives of therapies in clinical studies [71]. The origin of the 293 
excess of Aβ in the brain is not known, although both increased generation and unbalanced degradation are assumed 294 
[72]. The non-amyloidogenic pathway appears to be neuroprotective, while the amyloidogenic pathway generates 295 
neurotoxic Aβ peptides [73]. Both pathways compete with each other, since increasing α-secretase activity reduces 296 
production of the Aβ peptides [74,75]. BACE1 is regarded as a key target for therapeutic interventions in AD because it 297 
is one of the main responsible for Aβ generation in the brain [76,77]. Targeted deletion of BACE1 in APP transgenic 298 
mice completely abolishes the production and deposition of Aβ and also rescues memory deficits [78]. We found a 299 
reduction of the amyloidogenic secretase BACE1 by resveratrol in both 3xTg-AD and NoTg strains, thus indicating a 300 
shift to the non-amyloidogenic pathway of APP processing. Peptide sAPPβ was higher only in 3xTg-AD and resveratrol 301 
reduced the protein levels. One of the most important amyloid degrading enzymes is neprilysin, which plays a major 302 
role in degrading Aβ. Administration of resveratrol promoted the increase in neprilysin protein levels, contributing to 303 
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the anti-amyloidogenic effect of resveratrol in both strains. Gene or cell therapy mediated increase of neprilysin is 304 
sufficient to ameliorate AD-like phenotypes in several mouse models [79-81]. Our results suggest that resveratrol 305 
reduced Aβ load through the decrease of amyloidogenic secretase BACE1 and by means of the increase of amyloid-306 
degrading enzyme neprilysin levels. Supplementation of resveratrol also induced a trend toward increasing the levels of 307 
ADAM10 in both strains, altogether contributing to neuroprotection and cerebral resilience. SIRT1 decreases Aβ 308 
production [30,82,83]; therefore, activation of SIRT1 might at least partially mediate the anti-amyloid pathological 309 
effects of resveratrol. Resveratrol revealed outstanding protection against tau pathology in 3xTg-AD mice. Tau 310 
pathology is proposed to be triggered by amyloid pathology in the AD brain [84]. However, 3xTg-AD neurons, in 311 
addition to the APP and PS1 familial AD genes, express a human tauopathy gene, thus stressing tau pathology in this 312 
mouse model. Tau is one of the therapeutic targets in AD [85]. We found that the increase of p-tau levels in 3xTg-AD 313 
mice was paralleled by an increase in tau acetylation. Acetylation of lysine residues has been reported as a novel 314 
modification in the brain tissue of patients with AD and familial tauopathies [86-88]. Resveratrol administration 315 
reduced p-tau levels in 3xTg-AD mice, which may occur through the deacetylation of the tau protein by SIRT1, thereby 316 
favoring degradation of p-tau by the proteasome pathway. It is known that activation of SIRT1 pathway has a positive 317 
effect on the reduction of p-tau formation [86] and mice with a SIRT1 deletion show an accumulation of ac-tau in the 318 
brain [86,88]. 319 
The enhancement of proteolysis systems shown here by resveratrol may be chief in both prevention and therapy against 320 
AD and in neurodegenerative diseases coursing with the accumulation of aberrant proteins. We found a normalization 321 
of Hsp70 and ubiquitin levels in 3xTg-AD and a significant increase of proteasome levels and enzymatic activity in 322 
both NoTg and 3xTg-AD mice. UPS is the major proteolytic system that degrades aberrant proteins, including Aβ and 323 
p-tau [50]. Loss of proteasome activity increases the risk of AD, representing a clear link between this 324 
neurodegenerative disease and the aging process [40]. Functional proteasome degrades ubiquitin-tagged misfolded or 325 
aggregated proteins. Our results are in agreement with the previous observation that resveratrol promotes the 326 
intracellular degradation of Aβ in cell lines by a mechanism that implicates the proteasome [38]. SIRT1 is known to be 327 
involved in the maintenance of quality control of proteins mediated by UPS in vitro [30,89]; however, an effect of 328 
resveratrol on UPS activation had not been reported previously in vivo. The chaperone Hsp70 is involved in the 329 
degradation of aberrant proteins through interaction with CHIP and the ubiquitin E3 ligase [48,90,91]. Resveratrol 330 
induced a further decrease of Hsp70, in agreement with SIRT1 regulation [48], and also normalized ubiquitinated 331 
protein levels in 3xTg-AD mice, suggesting a recovery of UPS functionality. Proteasome 20S core subunits levels were 332 
decreased in 3xTg-AD mice, indicating impairment of the proteasome function, in agreement with previous results in 333 
AD brain tissue [92] and in hippocampal homogenates of 3xTg-AD mice [93]. Resveratrol enhanced the levels of 334 
proteasome 20S core subunits in both hippocampus and cortex tissue of NoTg and 3xTg-AD mice, and trypsin 335 
proteasomal activity in cerebral cortex of both strains of mice, suggesting an enhancement of UPS functionality. Some 336 
neurofibrillary tangles of p-tau are ubiquitinated [94,95], and neuronal death appears to be the end-point for 337 
neurofibrillary degeneration [96]. The increased yield of proteasome protein levels in brain tissue of 3xTg-AD mice 338 
would lead to the total degradation of aberrant Aβ and p-tau proteins, so that ubiquitinated proteins and Hsp70 were 339 
restored to baseline levels. Resveratrol also induced proteostasis enhancement in NoTg mice; thus, this is, to our 340 
knowledge, the first time reported that resveratrol increases proteasome function and ameliorates AD-like pathology in 341 
vivo. We highlight the increase of both the proteasome and neprilysin in the strain of NoTg mice, which would induce 342 
resilience against the accumulation of abnormal proteins. 343 
Although resveratrol was initially shown to directly activate SIRT1 in an assay utilizing a fluorophore-linked substrate 344 
[97], recent studies have shown that resveratrol indirectly activates SIRT1 due to its effect on cAMP signaling [34]. 345 
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SIRT1 is a nuclear localization protein [98] that, catalyzes the deacetylation of histones and several transcription factors 346 
through the consumption of the substrate NAD
+
 [29,99]. Resveratrol is thought to elicit its beneficial effects through 347 
upregulation of the AMPK/SIRT1 pathway [100-102]. It is suggested that resveratrol enhances AMPK activity, which 348 
in turn increases NAD
+
 concentration, resulting in the activation of SIRT1 [34,35,103]. Accordingly, AMPK-deficient 349 
mice showed to be resistant to the metabolic effects of resveratrol [101]. We found higher levels of p-AMPK in the 350 
hippocampus of both resveratrol-treated groups of mice; however, we did not observe changes in SIRT1 protein levels. 351 
In the inducible p25 transgenic mouse model of AD and tauopathies, introduction of resveratrol directly into the brain 352 
ventricles prevented learning impairment, reduced hippocampal neurodegeneration, and decreased acetylation of the 353 
SIRT1 substrate p53 [23]. SIRT1 induces neuroprotective effects against AD pathology through regulating the 354 
acetylation homeostasis of key proteins [29]. Accordingly, a decrease in p53 acetylation indicates SIRT1 activation in 355 
mouse hippocampus.  356 
The cyclic-AMP responsive element binding protein (CREB) is a basic leucine zipper transcription factor and a 357 
downstream target of ERK signaling during hippocampal-dependent learning [104]. The transcription of several 358 
downstream neuroprotective molecules is regulated by p-CREB. Deficiencies in CREB signaling have been linked to 359 
neurodegenerative processes and AD [105]. In previous studies, elevated p-CREB levels were found in the hippocampal 360 
CA1 region of resveratrol-treated rats [106]. Furthermore, it has been demonstrated that resveratrol can modulate 361 
learning and memory function by modulating SIRT1 and regulating p-CREB expression [60]. SIRT1 can regulate 362 
mitochondrial biogenesis, contributing to the maintenance of functional mitochondria [107]. It is also well-established 363 
that SIRT1 regulates the activity and acetylation status of PGC-1α [103,108,109], and many studies have pointed out 364 
the ability of resveratrol to upregulate PGC-1α activity[110], which results in beneficial changes in the mitochondrial 365 
function [100,111,112]. Previous studies indicate the deficiencies of mitochondrial complexes in 3xTg-AD mice [54] 366 
and elevated levels of oxidative lesions and alterations of antioxidant enzymes [52,113]. In this regard, we cannot 367 
discard some contribution of direct antioxidant mechanisms of reveratrol or other protective effects of this pleiotropic 368 
molecule [14,114]. Mitochondrial dysfunction is a molecular marker of aging that establishes a connection between 369 
aging and the risk of AD [115,116]. Mitochondrial dysfunction can be ameliorated by inducing PGC-1α via resveratrol-370 
mediated modulation of AMPK [117,118]. The enhancement of AMPK [35], PGC-1α [119] and CREB [60] pathways 371 
in all the mice treated with resveratrol corroborates the beneficial changes in mitochondrial function and plasticity 372 
processes, which will induce effector ways of protecting mitochondria, thus increasing the resilience of the brain. 373 




In summary, diet supplementation with resveratrol led to complete protection against memory loss in 3xTg-AD mice 376 
and to cognitive enhancement in healthy NoTg mice. Furthermore, resveratrol improved non-cognitive behaviors 377 
indicative of well-being in both mouse strains. Analysis of resveratrol administration in AD and healthy mice led to the 378 
uncovering of the following novel resveratrol mechanisms in vivo: i) activation of neprilysin and downregulation of 379 
BACE1, which reduces amyloid load; ii) enhancement of UPS, which leads to a reduction of aberrant amyloid and tau 380 
proteins, and iii) upregulation of AMPK/SIRT1 pathways, leading to an increase of PGC-1α and CREB. A schematic 381 
representation of the proposed mechanisms activated by resveratrol in this study is depicted in Fig. 6. The results 382 
depicted here suggest resveratrol-induced activation of SIRT1 as the main pathway inducing potent neuroprotective 383 
effects. This natural polyphenol has a potential in AD prevention by increasing brain resilience against aberrant 384 
proteins.  385 
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Figure Legends 397 
Fig. 1 Resveratrol treatment induced protection against BPSD-like behavior. Total number of rearings (a) and distance 398 
covered (b) in the Open field test. Latency of first-hole exploration (c) in the Boissier’s 4 hole-board test. Number of 399 
entries in the lit area (d), and time spent in the lit area (e) in the Dark & Light box test. Values are mean ± SEM (n = 10-400 
14). Statistical analysis: Two-way ANOVA, effect of genotype &&p < 0.01 and &&&p < 0.001; and effect of treatment 401 
$p < 0.05 and $$p < 0.01 402 
 403 
Fig. 2 Resveratrol administration induced protection against cognitive loss. NOR test at times 0h (a), 2h (b), and 24h 404 
(c). MWM test with distances covered to reach platform (d), distance covered in platform quadrant after removal (e), 405 
and swimming speed (f). Values are mean ± SEM (n = 8-14). Statistical analysis: c, e Two-way ANOVA, *p < 0.05 and 406 
***p < 0.001 compared to NoTg mice; #p < 0.05 and ##p < 0.01 compared to control treatment; d Two-way repeated 407 
measures ANOVA; b, f Two-way ANOVA, effect of genotype &p < 0.05; and effect of treatment $p < 0.05 and $$p < 408 
0.01 409 
 410 
Fig. 3 Resveratrol treatment protects against Aβ and tau pathology in hippocampus. Western blot analysis of total APP 411 
(a), APP-CTF (b), Aβ fragment (c), sAPPβ (d), BACE1 (e), neprilysin (f), total tau (g), p-tau (h) and ac-tau (i) in the 412 
hippocampus of 3xTg-AD and NoTg mice. Values are mean ± SEM (n = 4-8). Statistical analysis: a, d, f, g Two-way 413 
ANOVA, effect of genotype &&&p < 0.001; and effect of treatment $p < 0.05; b, c, e, h, i Two-way ANOVA, **p < 414 
0.01 and ***p < 0.001 compared to NoTg mice; #p < 0.05 and ##p < 0.01 compared to control treatment 415 
 416 
Fig. 4 Resveratrol administration enhances the activity of the ubiquitin-proteasome system. Protein analysis of Hsp70 417 
(a), ubiquitinated proteins (b) and proteasome 20S core subunits (c) in the hippocampus of 3xTg-AD and NoTg mice. 418 
Protein analysis of proteasome 20S core subunits (d) and proteasome trypsin-like activity (e) in the cerebral cortex 419 
tissue of 3xTg-AD and NoTg mice. Values are mean ± SEM (n = 5-11). Statistical analysis: a, b Two-way ANOVA, 420 
**p < 0.01 and ***p < 0.001 compared to NoTg mice; ##p < 0.01 compared to control treatment; c, d, e Two-way 421 
ANOVA, effect of treatment $$p < 0.01 422 
 423 
Fig. 5 Resveratrol administration activates SIRT1 pathway by activation of p-AMPK. Protein analysis of SIRT1 (a), 424 
ratio of p53 acetylated to total p53 (b), ratio of p-AMPK to total AMPK (c), ratio of p-CREB to total CREB (d), and 425 
PGC-1α (e) in the hippocampus of 3xTg-AD and NoTg mice. Values are mean ± SEM (n = 5-7). Statistical analysis: 426 
Two-way ANOVA, effect of genotype &&p < 0.01; and effect of treatment $p < 0.05, $$p < 0.01 and $$$p < 0.001 427 
 428 
Fig. 6 Proposed pathways involved in the neuroprotective effects of resveratrol administration, leading to a reduction in 429 
AD-like pathology through proteostasis enhancement. See text for discussion of mechanisms. Abbreviations: Ac, 430 
acetylated; Aβ, amyloid-β; AD, Alzheimer’s disease; ADAM10, a disintegrin and metalloproteinase 10; AMPK, 431 
adenosine monophosphate-activated protein kinase; BACE1, beta-site APP cleaving enzyme 1; CREB, cAMP response 432 
element-binding protein; PGC-1α, peroxisome proliferator-activated receptor-γ coactivator 1α; p-tau, 433 
hyperphosphorylated tau; UPS, ubiquitin proteasome system. 434 
 435 
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Supplementary Table 1 
 
List of primary antibodies used in Western blotting (WB) 
Antibody Dilution Source Catalog Nº 
    
Aβ, clone 6e10 1:1000 BioLegend 803001 
sAPPα 1:500 BioLegend 813501 
sAPPβ 1:1000 BioLegend 813401 
APP-CTF, clone C1/6.1 1:1000 Covance SIG-39152 
Actin (20-33) 1:10 000 Sigma A5060 
ADAM10 1:1000 Abcam  ab1997 
AMPK 1:1000 Cell Signaling 2532S 
p-AMPK (Thr172) 1:1000 Cell Signaling 2535S 
BACE1 1:1000 Abcam ab2077 
CREB 1:1000 Cell Signaling 9197S 
p-CREB (Ser133) 1:1000 Cell Signaling 9196S 
Hsp70 (W27) 1:2000 Calbiochem HSP01 
IDE 1:1000 Calbiochem PC730 
Neprilysin/CD10 1:1000 R&D system AF1126 
ac-p53, acetyl K382 1:1000 Abcam  ab37318 
PGC-1α 1:500 Santa Cruz Biotechnology sc-13067 
Proteasome 20S core 1:1000 Enzo Life Sciences  BML-PW8155 
PSD95 1:500 Millipore MAB1598 
SIRT1 1:2500 Cell Signaling 2028s 
Synaptophysin 1:10 000 Dako A0010 
ac-tau, acetyl K280 1:500 AnaSpec 56077 
p-tau, clone AT8  1:1000 Thermo Scientific MN1020 
Total tau, clone HT7 1:1000 Thermo Scientific MN1000 
β-tubulin 1:10000 Sigma T4026 





Supplementary Fig. 1 Resveratrol administration has minor effect on the non-amyloidogenic pathway and IDE. 
Protein analysis of sAPPα peptide (a), ADAM10 (b) and IDE (c) in the hippocampus of 3xTg-AD and NoTg mice. 





Supplementary Fig. 2 Resveratrol administration does not modulate chymotrypsin-like and caspase-like activity. 
Chymotrypsin-like activity (a) and Caspase-like activity (b) in the cortex tissue of 3xTg-AD and NoTg mice. Values 





Supplementary Fig. 3 Resveratrol does not modulate neurotrophism or plasticity. Relative protein levels for PSD95 (a) 
and Synaptophysin (b) in the hippocampus of 3xTg-AD and NoTg mice. Values are mean ± SEM (n = 5-7). Statistical 
analysis: Two-way ANOVA, effect of genotype &p < 0.05. 
